Positron emission tomography imaging of small animals in anticancer drug development

被引：16

作者：

Aboagye, Eric O. ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Ctr Clin Sci, Mol Therapy & PET Oncol Res Grp, London W12 0NN, England

来源：

MOLECULAR IMAGING AND BIOLOGY | 2005年 / 7卷 / 01期

基金：

英国医学研究理事会; 英国惠康基金;

关键词：

small animal imaging; PET; anticancer; drug development;

D O I：

10.1007/s11307-005-0886-2

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Positron emission tomography (PET) imaging of small animals enables researchers to bridge the gap between in vitro science and in vivo human studies. The imaging paradigm can be established and refined in animals before implementation in humans and image data related to ex vivo assays of biological activity. Small animal PET (saPET) imaging enables assessment of baseline focal pathophysiology, pharmacokinetics, biological target modulation and the efficacy of novel drugs. The potential and challenge of this technology as applied to anticancer drug development is discussed here.

引用

页码：53 / 58

页数：6

共 37 条

[1]

Aboagye E. O, 2002, ANTICANCER DRUG DEV, P353

[2] Use of positron emission tomography in anticancer drug development [J].